Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
Eur J Med Chem ; 76: 397-407, 2014 Apr 09.
Article in English | MEDLINE | ID: mdl-24602785

ABSTRACT

Four new copper(II) complexes containing phosphonium substituted hydrazone (L) with the formulations [CuL]Cl(3), [Cu(phen)L]Cl(4), [Cu(bpy)L]Cl(5), [Cu(dbpy)L]Cl(6), (where L = doubly deprotonated hydrazone; phen = 1,10'-phenanthroline; bpy = 2,2'-bipyridine; dbpy = 5,5'-dimethyl-2,2'-bipyridine) have been synthesized. The compounds were characterized by elemental analysis, spectroscopic methods and in the case of crystalline products by X-ray crystallography. The cytotoxicity and topoisomerase I (topo I) inhibition activities of these compounds were studied. It is noteworthy that the addition of N,N-ligands to the copper(II) complex lead to the enhancement in the cytotoxicity of the compounds, especially against human prostate adenocarcinoma cell line (PC-3). Complex 4 exhibits the highest activity against PC-3 with the IC50 value of 3.2 µΜ. The complexes can also inhibit topo I through the binding to DNA and the enzyme.


Subject(s)
Copper/chemistry , Hydrazones/chemistry , Hydrazones/pharmacology , Phosphorus/chemistry , Topoisomerase I Inhibitors/chemistry , Topoisomerase I Inhibitors/pharmacology , Cell Line, Tumor , Crystallography, X-Ray , Drug Screening Assays, Antitumor , Humans , Ligands , Magnetic Resonance Spectroscopy , Models, Molecular , Spectrophotometry, Infrared
SELECTION OF CITATIONS
SEARCH DETAIL
...